Think of Verquvo as a "Niche" Med for Heart Failure

You'll hear once-daily vericiguat (Verquvo) is a new add-on for worsening heart failure with reduced ejection fraction (HFrEF).

Vericiguat is the first "soluble guanylate cyclase stimulator" for HFrEF. It relaxes blood vessels through the nitric oxide pathway.

Most evidence is in patients already on triple ACEI, ARB, or sacubitril/valsartan (Entresto), beta-blocker (carvedilol, etc), AND aldosterone antagonist (spironolactone, etc).

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals